Bio-Thera Strikes Strategic Deal With Jamjoom Pharma For Securing Cosentyx Biosimilar In MENA

Bio-Thera Solutions Inc., a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars and Jamjoom Pharmaceuticals Factory Company (Jamjoom Pharma), one of the fastest-growing pharmaceutical companies in the Middle East and Africa, announced the signing of a strategic commercialization agreement for BAT2306, a biosimilar referencing Cosentyx.

Under the agreement, Jamjoom Pharma will obtain the exclusive rights to commercialize BAT2306 - a proposed biosimilar to Novartis’ Cosentyx (secukinumab) - across the Middle East and North Africa (MENA) region. Jamjoom Pharma will manage regulatory submissions, market access, and commercialization in MENA, while Bio-Thera will oversee product development and global manufacturing from its state-of-the-art facilities in Guangzhou, China.

"This collaboration is a strategic milestone for Jamjoom Pharma and a testament to our mission of broadening access to advanced biologics in the MENA region,”said Tarek Hosni, Chief Executive Officer of Jamjoom Pharma. "By joining forces with Bio-Thera, we are combining world-class biosimilar development with Jamjoom’s deep regional expertise, strong commercial capabilities, and commitment to delivering high-quality, affordable therapies. This agreement strengthens our leadership in the biopharmaceutical sector and reinforces our role as a trusted partner in improving patient outcomes."

"Bio-Thera is committed to bringing affordable medicines to patients in need around the world," said Bert Thomas, Senior Vice President of Business Development. "Partnering with JamJoom Pharma to bring BAT2306 to patients in the MENA region is a demonstration of that commitment. We are proud to partner with Jamjoom Pharma and look forward to a successful collaboration."

About Bio-Thera Solutions
Bio-Thera Solutions, Ltd., a leading innovative, global biopharmaceutical company in Guangzhou, China, is dedicated to researching and developing novel therapeutics for the treatment of cancer, autoimmune, cardiovascular, eye diseases, and other severe unmet medical needs, as well as biosimilars for existing, branded biologics to treat a range of cancer and autoimmune diseases. As a leader in next generation antibody discovery and engineering, the company has advanced multiple candidates into late-stage development, including five approved products: Qletli (adalimumab) in China and the UK, BETAGRIN (bevifibatide citrate injection) in China, STARJEMZA (ustekinumab) in the US and Usymro (ustekinumab) in EU, and TOFIDENCE/BAT1806 (tocilizumab) and AVZIVI (bevacizumab-tnjn) in the US and in EU, a/k/a POBEVCY in China. In addition, the company has more than 20 promising candidates in clinical trials, focusing on immuno-oncology in the post-PD-1 era and targeted therapies such as antibody-drug conjugates (ADCs). For more information, visit www.bio-thera.com/en/.

About Jamjoom Pharma (Jamjoom Pharmaceuticals Factory Company)
Jamjoom Pharma is a leading pharmaceutical organization committed to enhancing the quality of life through the development, manufacturing, and distribution of high-quality medicines and consumer healthcare products. Headquartered in Saudi Arabia, the company was established back in 2000 and is tirelessly operating to support the Saudi Vision 2030 to reinforce the public healthcare system. With a strong focus on patient-centered care, Jamjoom Pharma serves diverse markets across Middle East & Africa, with a bold ambition for more expansion, providing effective solutions in key therapeutic areas (including ophthalmology, dermatology, cardiometabolic, gastrointestinal, and general medicine). Through its state-of-the-art facilities and established distribution channels across the MEA region and dedication to regulatory excellence, Jamjoom Pharma continues to deliver products that meet the highest standards of safety, efficacy, and quality, improving health outcomes for millions of people.